Prospective Non-Randomized Phase II Study of Neoadjuvant Camrelizumab Combined With Paclitaxel and Carboplatin in Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity and Larynx (Stage III-IVA)
Latest Information Update: 17 Feb 2026
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Laryngeal cancer; Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NeoCamre-HN
Most Recent Events
- 17 Feb 2026 New trial record